National Library of Medicine (NCBI)
From David Wood Political Editor, From George Clark Political Staff, By Peter Evans Home Affairs Correspondent, From Our Political Staff, From David Cross, From Christopher Sweeney, From Paul Routledge Labour Correspondent, From Fred Emery, From Our Correspondent, By Christopher Walker, From John Chartres, By John Clare, From Clive Borrell, By Arthur Reed, Air Correspondent, By Our Environment Reporter, By a Staff Reporter, By Our Air Correspondent, By Our Parliamentary Staff, From Our Parliamentary Staff, From Roger Berthoud, From Patricia Clough, From Our Own Correspondent, From Charles Hargrove, From Peter Nichols, From Michael Leapman, From Harry Debelius, From Michael Leapman Chicago, From Ian McDonald, David Pryce-Jones, From Peter Strafford, Robert Nye, H. R. F. Keating, From Harry Golombek, Michael Ratcliffe, Bevis Hillier, William Haley, Michael Holroyd, John Higgins, By Geoffrey Green Football Correspondent, By John Hopkins, By Peter West Rugby Correspondent, By Norman Fox, By Peter Marson, By Tom German, By Gerry Harrison, From St John Donn-Byrne French Racing Correspondent, By Jim Snow Northern Racing Correspondent, By Peter Ryde Golf Correspondent, By Pamela MacGregor-Morris, by Penny Radford, Leonard Amey, Ronald Butt, Bernard Levin, PHS, Renée Short, S. E. ELLISON., J. E HUMPHREY, , PEREGRINE FELLOWES, MANFRED SIMON, , NEIL MARTEN, , GORDON TOMPSON, , EILEEN R. POOL, , JOHN SELWYN GUMMER, , EGON RONAY., DIANA MOSLEY., MAREA HARTMAN, , NANCY TENNANT., From Mr S. Gordon, S. GORDON, , SALLY OPPENHEIM, , SIMON YOUNG., From Sir Robert Lusty, ROBERT LUSTY, By Geraldine Norman Sale Room Correspondent, By Basil Gingell Religious Affairs Correspondent, By Philip Howard, By Ian Morison, By Dennis Dwyer, By Maurice Corina Industrial Editor, By Christopher Marley Financial Editor, By Malcolm Brown, By Peter Hill, By Philip Dyer, By Maurice Barnfather, By Clifford Webb, BY THE FINANCIAL EDITOR, F. R. COAD., By Our Industrial Editor, From Mr A. C. Morton, A. C. MORTON, Secretary, , ROY CARDY., By Roger Vielvoye, From Frank Vogl, ERNEST M. PAYNE, , HANS RENOLD., Peter Jay, By Our Northern Industrial Correspondent, By Our Agricultural Correspondent, Eynon Smart, Philip Dyer, Richard Blythe, Stuart Marshall,
... told the Cabinet in 1967, Drugs: Effect of levodopa in pregnancy, Yugoslavia keeps lead in chess Olympiad, ...
1972 - Gale Group | TDA
Alberto J. Espay, Fabrizio Stocchi, Rajesh Pahwa, Alberto Albanese, Aaron Ellenbogen, Joaquim J. Ferreira, Nir Giladi, Tanya Gurevich, Sharon Hassin‐Baer, Jorge Hernández‐Vara, Stuart Isaacson, Karl Kieburtz, Peter A. LeWitt, Lydia López Manzanares, C. Warren Olanow, Werner Poewe, Harini Sarva, Tami Yardeni, Liat Adar, Laurence Salin, Nelson Lopes, Noah J. Sasson, Ryan Case, Olivier Rascol, Mitra Afshari, А. В. Амелин, David Arkadir, Samih Badarny, Ernest Balaguer Martinez, Andrzej Bogucki, James T. Boyd, Laura Buyan Dent, Camille Carroll, К. Ray Chaudhuri, Jeffrey W. Cooney, Anne-Gaëlle Corbillé, Téodor Danaila, Maria Francesca De Pandis, Sophie Dethy, Rohit Dhall, Ruth Djaldetti, Franck Durif, Stephen Flitman, Eric Freire Alvarez, John L. Goudreau, Francisco Grandas Perez, Tanya Gurevich, Arnaldo Isa, Jorge L. Juncos, Sulada Kanchana, Gabriela Kłodowska-Duda, Dariusz Koziorowski, J. Kulisevsky Bojarski, Juan Lopez Lozano, Lan Luo, N. V. Lytvynenko, Roberto Marconi, Ana Marqués, Juan Carlos Martínez‐Castrillo, Irene Martínez‐Torres, Aashoo Mentreddi, Pablo Mir Rivera, Sergii Moskovko, Y. N. Neryanova, Marco Onofrj, Jill L. Ostrem, Claudio Pacchetti, Nicola Pavese, Clelia Pellicano, Gonzalo J. Revuelta, Margarida Rodrigues, Ramon L. Rodriguez, Monika Rudzińska, Nighat Sarwar, Julie Schwartzbard, Laura Scorr, John T. Slevin, Tatyana Slobodin, Gianfranco Spalletta, Michele Tagliati, Yen Tai, Alessandro Tessitore, Peter Valkovič, Leo Verhagen, Е. А. Вострикова, Gilad Yahalom, Zuleykha Zalyalova, Kateřina Zárubová, Irina Zhukova,
Background Conventional oral levodopa therapy for the treatment of Parkinson's disease can be associated with variations in plasma concentrations. Levodopa infusion strategies might provide more consistent drug delivery ... 24 h/day subcutaneous infusion of ND0612 (a levodopa–carbidopa solution) compared with oral immediate-release levodopa–carbidopa for the treatment of motor fluctuations in ... regimens were established for both oral immediate-release levodopa–carbidopa and for 24 h/day subcutaneous ND0612 ...
Tópico(s): Botulinum Toxin and Related Neurological Disorders
2024 - Elsevier BV | The Lancet Neurology
Directory of Open Access Books (DOAB)
Produção Nacional
Revisado por pares
Jamie A. F. Jansen, Tamine Capato, Sirwan K.L. Darweesh, Egberto Reis Barbosa, Rogier Donders, Bastiaan R. Bloem, Jorik Nonnekes,
... FOG) in Parkinson’s disease (PD) is complex: levodopa is the most effective symptomatic treatment for FOG, but long-term pulsatile levodopa treatment has also been linked to an increase ... we compared the occurrence of FOG between a levodopa-naive PD cohort and a levodopa-treated cohort. Forty-nine treatment-naive patients and 150 levodopa-treated patients were included. The time since first ... The presence of FOG was compared between the levodopa-treated and levodopa-naive groups using a chi-square test of ...
Tópico(s): Genetic Neurodegenerative Diseases
2023 - Nature Portfolio | npj Parkinson s Disease
National Library of Medicine (NCBI)
Valentina Leta, Lisa Klingelhoefer, Katherine Longardner, Marta Campagnolo, Hafize Çotur Levent, Federico Aureli, Vinod Metta, Roongroj Bhidayasiri, Guy Chung‐Faye, Cristian Falup‐Pecurariu, Fabrizio Stocchi, Peter Jenner, Tobias Warnecke, К. Ray Chaudhuri,
Levodopa is the gold standard for the symptomatic treatment of Parkinson's disease (PD). There are well ... motor fluctuations, however, that occur almost inevitably once levodopa is started after a variable period in people ... barriers across the gastrointestinal (GI) tract can alter levodopa pharmacokinetics, ultimately contributing to non-optimal levodopa response and symptoms fluctuations. GI barriers to levodopa transport and absorption include dysphagia, delayed gastric emptying, ... diet and concomitant medication intake can further alter levodopa pharmacokinetics. This can result in unpredictable or sub- ...
Tópico(s): Gastrointestinal motility and disorders
2023 - Wiley | European Journal of Neurology
National Library of Medicine (NCBI)
Robert A. Hauser, Alberto J. Espay, Aaron Ellenbogen, Hubert H. Fernandez, Stuart Isaacson, Peter A. LeWitt, William G. Ondo, Rajesh Pahwa, Johannes Schwarz, Fabrizio Stocchi, Leonid Zeitlin, Ghazal Banisadr, Stanley E. Fisher, Hester Visser, Richard D’Souza,
Levodopa has a short half-life and a limited window of opportunity for absorption in the proximal ... is an oral, extended-release formulation of carbidopa-levodopa developed to address these limitations.To assess the ... and safety of IPX203 vs immediate-release carbidopa-levodopa in patients with Parkinson disease who are experiencing ... daily dose of 400 mg or more of levodopa and experiencing an average of 2.5 hours ... 140 were excluded (those taking controlled-release carbidopa-levodopa apart from a single daily bedtime dose, Rytary ( ...
Tópico(s): Neurological disorders and treatments
2023 - American Medical Association | JAMA Neurology
National Library of Medicine (NCBI)
Adina Wise, Hernan Nicolás Lemus, Madeline Fields, Matthew Swan, Susan Bressman,
Carbidopa-levodopa has been used for more than 50 years in the treatment of Parkinson disease (PD) and other ... B6 (pyridoxine), is involved in the decarboxylation of levodopa to dopamine; carbidopa, which is combined with levodopa to reduce peripheral levodopa conversion and minimize peripheral dopamine side effects, binds irreversibly with PLP. As a result, carbidopa-levodopa may cause vitamin B6 deficiency and associated sequelae, ... a 6-year history of PD on carbidopa-levodopa therapy and recent weight loss presented with new- ...
Tópico(s): RNA regulation and disease
2022 - Karger Publishers | Case Reports in Neurology
Yasuhiko Baba, Akinori Futamura, Ryuta Kinno, Shohei Nomoto, Seiya Takahashi, Taro Yasumoto, Yuyuko Osakabe, Daiki Shoji, Yoko Nabeshima,
In Japan, only two medications of immediate-release levodopa with distinct ratios of decarboxylase inhibitor (DCI), namely levodopa/benserazide 100/25 mg and levodopa/carbidopa 100/10 mg, are available for the ... relationship between the difference in the DCI to levodopa ratio and the development of motor complications in long-term administration of levodopa is unknown.We assessed the duration from initiation of levodopa/DCI to the emergence of motor fluctuations in patients with PD treated with levodopa/benserazide and levodopa/carbidopa.We retrospectively assessed the ...
Tópico(s): Genetic Neurodegenerative Diseases
2022 - Elsevier BV | Journal of the Neurological Sciences
Yi Zhang, Xiaoqin He, Chengjun Mo, Xiaoqian Liu, Jian Li, Yan Zheng, Yiwei Qian, Yiqiu Lai, Shaoqing Xu, Xiaodong Yang, Qin Xiao,
Background and Objectives Interindividual variability in levodopa efficacy is a challenge for the personalized treatment of Parkinson disease (PD). Gut microbiota might represent a new approach for personalized medicine. Recently, a novel microbial levodopa metabolism pathway was identified, which is mediated by ... tyrDC gene and E faecalis is associated with levodopa responsiveness and could predict the drug response. Methods ... between December 2019 and January 2022 and evaluated levodopa responsiveness using a levodopa challenge test. Patients were ...
Tópico(s): GABA and Rice Research
2022 - Lippincott Williams & Wilkins | Neurology
Filip Bergquist, M. Ehrnebo, Dag Nyholm, Anders Johansson, Fredrik Lundin, Per Odin, Per Svenningsson, Fredrik Hansson, L. G. Bring, Elias Eriksson, Nil Dizdar,
Intestinal levodopa/carbidopa gel infusion (LCIG) is superior to oral treatment in advanced Parkinson disease. The primary objective of ... or intravenous infusion with a continuously buffered acidic levodopa/carbidopa solution yields steady-state plasma concentrations of levodopa that are equivalent in magnitude, and noninferior in ... patients with advanced Parkinson disease.A concentrated acidic levodopa/carbidopa (8:1) solution buffered continuously and administered ... DIZ101 and DIZ102 vs LCIG with respect to levodopa plasma concentrations.With dosing adjusted to estimated bioavailability, ...
Tópico(s): Neurological disorders and treatments
2022 - Lippincott Williams & Wilkins | Neurology
M. Dileone, Claudia Ammann, Valentina Catanzaro, Cristina Pagge, Rosanna Piredda, Mariana H.G. Monje, Irene Navalpotro‐Gómez, Alberto Bergareche, María Rodríguez‐Oroz, Lydia Vela, Fernando Alonso‐Frech, María José Catalán, José Alberto Molina, Nuria López-Ariztegu, Antonio Oliviero, José Á. Obeso, Guglielmo Foffani,
... may provide subjective benefit for the treatment of levodopa-induced dyskinesias. Levodopa-induced dyskinesias are a common complication in patients with Parkinson's disease (PD) treated chronically with levodopa. Even though dyskinesias may be more tolerable than ... magnetic stimulation (rTMS) may be effective for reducing levodopa-induced dyskinesias [[1]Wu Y. Cao X. Zeng ... Yang X. et al.Transcranial magnetic stimulation alleviates levodopa-induced dyskinesia in Parkinson's disease and the ... novel non-invasive home-based treatment to manage levodopa-induced dyskinesias.1. MethodsWe conducted a randomized, sham- ...
Tópico(s): Neuroscience and Neural Engineering
2022 - Elsevier BV | Brain stimulation
Thomas Müller, Eugen Schlegel, Stephanie Zingler, Hans Michael Thiede,
... and opicapone prolong the efficacy of conventional oral levodopa/dopa decarboxylase inhibitor formulations through an increase in levodopa plasma bioavailability. Catechol-O-methyltransferase inhibitors influence the homocysteine metabolism associated with levodopa/dopa decarboxylase application. The objectives of this study ... opicapone intake on the pharmacokinetic plasma behaviour of levodopa, 3-O-methyldopa and total homocysteine in 15 ... received opicapone plus two doses of 100 mg levodopa/carbidopa and, one week later, two doses of ...
Tópico(s): Attention Deficit Hyperactivity Disorder
2022 - Multidisciplinary Digital Publishing Institute | Cells
Abhishek Lenka, Gianluca Di Maria, Guillaume Lamotte, Laxman Bahroo, Joseph Jankovic,
Introduction Levodopa is the most effective medication for the treatment of motor symptoms of Parkinson's disease (PD). Several factors may affect the efficacy and tolerability of levodopa. These include the timing, dosage and administration of levodopa, concomitant drugs, food, PD-associated non-motor symptoms, ... If not appropriately addressed, these issues may limit levodopa efficacy, tolerability, and compliance.Areas covered This article ... the basics of the metabolism of orally administered levodopa, its side effects, and the factors that may ...
Tópico(s): Child Nutrition and Feeding Issues
2022 - Taylor & Francis | Expert Review of Neurotherapeutics
Peter A. LeWitt, Fabrizio Stocchi, David Arkadir, Yoseph Caraco, Liat Adar, Itay Perlstein, Ryan Case, Nir Giladi,
While treatment with levodopa remains the cornerstone of Parkinson's disease (PD) management, chronic oral therapy is often associated with the development of motor complications, that correlate to fluctuating levodopa plasma concentrations, limiting its clinical utility. Continuous infusion ... systems require invasive surgery. Subcutaneous infusion of (SC) levodopa has the potential to provide a better tolerated and more convenient route of continuous levodopa delivery. ND0612 is in development as a combination ...
Tópico(s): Botulinum Toxin and Related Neurological Disorders
2022 - Frontiers Media | Frontiers in Neurology
Kaifei Xu, Shuo Sheng, Feng Zhang,
... reduction of dopamine neurons in the substantia nigra. Levodopa, as a dopamine supplement, is the gold-standard therapeutic drug for PD. The metabolism of levodopa in the periphery not only decreases its bioavailability ... efficacy. Thus, it is necessary to investigate how levodopa is metabolized. A growing number of studies have ... faecalis, Eggerthella lenta and Clostridium sporogenes, could metabolize levodopa in different ways. In addition, several pathways to reduce levodopa metabolism by gut microbiota were confirmed to improve ...
Tópico(s): Ginger and Zingiberaceae research
2022 - Bentham Science Publishers | Current Neuropharmacology
Joaquim J. Ferreira, Werner Poewe, Olivier Rascol, Fabrizio Stocchi, Angelo Antonini, Joana Moreira, Bruno Martini Guimarães, José‐Francisco Rocha, Patrı́cio Soares-da-Silva,
... O-methyltransferase extends the plasma half-life of levodopa, potentially allowing physicians to optimize the levodopa regimen in patients with Parkinson's disease (PD) ... evaluate the effects of once-daily opicapone on levodopa plasma pharmacokinetics and motor response when added to two different levodopa dosing regimens.A total of 24 patients with ... label, modified cross-over trial. Participants first received levodopa/carbidopa 500/125 mg (five intakes) for 2 ... and were then randomly assigned (1:1) to levodopa/carbidopa 400/100 mg given over either four ...
Tópico(s): Attention Deficit Hyperactivity Disorder
2022 - Wiley | Movement Disorders
Takashi Ogawa, Taku Hatano, Koji Kamagata, Christina Andica, Haruka Takeshige‐Amano, Wataru Uchida, Yuya Saito, Yasushi Shimo, Genko Oyama, Atsushi Umemura, Hirokazu Iwamuro, Masanobu Ito, Masaaki Hori, Shigeki Aoki, Nobutaka Hattori,
Levodopa-induced dyskinesia is a complication of levodopa therapy and negatively impacts the quality of life of patients. We aimed to elucidate white matter alterations in Parkinson's disease with levodopa-induced dyskinesia using advanced diffusion magnetic resonance imaging ... 26 clinically confirmed Parkinson's disease patients without levodopa-induced dyskinesia, 25 Parkinson's disease patients with levodopa-induced dyskinesia, and 23 healthy controls. Subjects were ... analysis was used to calculate odds ratios for levodopa-induced dyskinesia.Group-wise tract-based spatial statistical ...
Tópico(s): Neurological disorders and treatments
2021 - Elsevier BV | Parkinsonism & Related Disorders
Dimitrios J. Palidis, Heather E. McGregor, Andrew Vo, Penny A. MacDonald, Paul L. Gribble,
... in motor adaptation by administering the dopamine precursor levodopa to healthy participants in two experiments involving reaching movements. Levodopa has been shown to impair reward-based learning in cognitive tasks. Thus, we hypothesized that levodopa would selectively impair aspects of motor adaptation that ... potentials evoked by task feedback. We hypothesized that levodopa would specifically diminish adaptation and the neural responses to feedback in the reward learning task. However, levodopa did not affect motor adaptation in either task ...
Tópico(s): Neural and Behavioral Psychology Studies
2021 - American Physiological Society | Journal of Neurophysiology
Emma McIntosh, Seamus Kent, Alastair Gray, Carl E Clarke, Adrian Williams, Crispin Jenkinson, Natalie Ives, Smitaa Patel, Caroline Rick, Keith Wheatley, Richard Gray,
... and quality of life from initiating therapy with levodopa compared with levodopa‐sparing therapies in early Parkinson's disease (PD). ... objective was to estimate the cost‐effectiveness of levodopa‐sparing therapy (dopamine agonists or monoamine oxidase type B inhibitors compared with levodopa alone. Methods PD MED is a pragmatic, open‐ ... newly diagnosed with PD were randomly assigned between levodopa‐sparing therapy (dopamine agonists or monoamine oxidase type B inhibitors ) and levodopa alone. Mean quality‐adjusted life‐years and costs ...
Tópico(s): Neurological disorders and treatments
2021 - Wiley | Movement Disorders
Eva Schaeffer, Thomas Vaterrodt, Laura Zaunbrecher, Inga Liepelt‐Scarfone, Kirsten Emmert, Benjamin Röeben, Morad Elshehabi, Clint Hansen, Sara Becker, Susanne Nussbaum, Jan‐Hinrich Busch, Matthis Synofzik, Daniela Berg, Walter Maetzler,
... nocturnal akinesia being one of the most burdensome. Levodopa is frequently used in clinical routine to improve ... is not well proven.We assessed associations of Levodopa intake with quality of sleep and perception of ... in total n = 1124 PD patients), patients taking Levodopa CR reported a significantly higher burden by nocturnal akinesia than patients without Levodopa. Higher Levodopa intake and MDS-UPDRS part IV scores (indicating ... while disease duration and severity were not predictive. Levodopa intake was not associated with objectively changed mobility ...
Tópico(s): Restless Legs Syndrome Research
2021 - Springer Science+Business Media | Journal of Neurology
Natalia Palacios, Anas Hannoun, Julie Flahive, Doyle V. Ward, Kelsey Goostrey, Anindita Deb, Kara Smith,
Background: The impact of Levodopa on the gut microbiota of Parkinson's disease (PD) patients has not been sufficiently addressed. Methods: We conducted a longitudinal study to examine the impact of Levodopa initiation on the gut microbiota composition of 19 ... patients who had not previously been exposed to Levodopa. Patients provided two stool samples prior to and two samples 90 days after starting Levodopa. Motor impairment (MDS-UPDRS Part III), diet, and ... examined, cross-sectionally and longitudinally, the associations between Levodopa use and alpha and beta diversity and performed ...
Tópico(s): Botulinum Toxin and Related Neurological Disorders
2021 - Frontiers Media | Frontiers in Neurology
Chumpol Anamnart, Ram Kitjarak,
... significant increase in plasma homocysteine (Hcy) levels in levodopa-treated Parkinson's disease (PD) patients, and vitamin ... the effects of catechol-O-methyltransferase inhibitors on levodopa-induced increase in Hcy levels were conflicting. The ... to evaluate whether Hcy levels are increased in levodopa-treated PD patients and to evaluate the effects ... and folate or entacapone on Hcy levels in levodopa-treated PD patients. Methods We analyzed and compared plasma Hcy levels in 20 levodopa-naïve PD patients and 42 levodopa-treated PD ...
Tópico(s): RNA regulation and disease
2021 - Elsevier BV | Journal of Clinical Neuroscience
Jikke T Boelens Keun, Ilse A.C. Arnoldussen, Chris Vriend, Ondine van de Rest,
Although levodopa remains the most effective drug for symptomatic management of Parkinson's Disease (PD), treatment during advanced disease ... have investigated nutritional support specifically with respect to levodopa therapy. With this systematic review, we aim to ... a comprehensive overview of dietary approaches to optimize levodopa treatment in PD. A systematic search was performed ... 2020. Nutritional interventions with the rationale to optimize levodopa therapy in human PD patients were eligible for ...
Tópico(s): Child Nutrition and Feeding Issues
2021 - Elsevier BV | Advances in Nutrition
Kate Thomson, Ian G. Morgan, Tamsin Kelly, Cindy Karouta, Regan Ashby,
Purpose: Topical application of levodopa inhibits the development of form-deprivation myopia (FDM) and lens-induced myopia (LIM) in chicks. Here we examine whether coadministration ... mechanism by which they inhibit experimental myopia. Methods: Levodopa and levodopa:carbidopa (at a 4:1 ratio) were administered ... mass spectrometry following topical or systemic administration of levodopa or levodopa:carbidopa. Finally, chicks receiving topical or systemic levodopa or levodopa:carbidopa were cotreated with the dopamine ...
Tópico(s): Ophthalmology and Visual Impairment Studies
2021 - Cadmus Press | Investigative Ophthalmology & Visual Science
Cheng Zhou, Tao Guo, Jingjing Wu, Linbo Wang, Xueqin Bai, Ting Gao, Xiaojun Guan, Luyan Gu, Peiyu Huang, Min Xuan, Quanquan Gu, Xiaojun Xu, Baorong Zhang, Wei Cheng, Jianfeng Feng, Minming Zhang,
... responsiveness of Parkinson's disease (PD) patients to levodopa is an important clinical issue because of its ... the locus coeruleus (LC) attenuates the efficacy of levodopa treatment.To explore the relationship between LC degeneration and levodopa responsiveness in PD patients in vivo.Neuromelanin-sensitive ... of LC and substantia nigra (SN) degeneration, and levodopa challenge tests were conducted in 57 PD patients. Responsiveness to levodopa was evaluated by the rates of change of ... from resting-state functional MRI before and after levodopa administration. Next, we assessed the relationship between the ...
Tópico(s): Transcranial Magnetic Stimulation Studies
2021 - IOS Press | Journal of Parkinson s Disease
Karsten Mueller, Dušan Urgošík, Tommaso Ballarini, Štefan Holiga, Harald E. Möller, Filip Růžička, Jan Roth, Josef Vymazal, Matthias L. Schroeter, Evžen Růžička, Robert Jech,
Levodopa is the first-line treatment for Parkinson's disease, although the precise mechanisms mediating its efficacy ... elusive. We aimed to elucidate treatment effects of levodopa on brain activity during the execution of fine ... performed after withdrawal and administration of a single levodopa dose. A subgroup of patients (n = 18) repeated ... electrode implantation with stimulator on and off. Investigating levodopa treatment, we found a significant interaction between both ... motor regions. Specifically, during the off state of levodopa medication, activity in the putamen at rest was ...
Tópico(s): Transcranial Magnetic Stimulation Studies
2020 - Oxford University Press | Brain Communications